ATTBF OTC
Abattis Bioceuticals Corp.
1W: -96.7%
1M: -96.7%
3M: -96.7%
YTD: -96.7%
1Y: -96.7%
3Y: -90.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$9M
+213.7% ▲
Capital Expenditures
$5M
-2065.1% ▼
5Y CAGR: +61.2%
Free Cash Flow
$4M
+151.1% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$2M
-157.8% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$6M | -$2M | -$8M | -$78M | -$3M |
| Depreciation & Amort. | $183K | $130K | $121K | $37K | $109K |
| Stock-Based Comp. | $241K | $68K | $719K | $495K | $2K |
| Change in Working Capital | $536K | $309K | $188K | -$712K | $8M |
| Other Non-Cash Items | $3M | $1M | $6M | $52M | $5M |
| Operating Cash Flow | -$2M | -$733K | -$1M | -$8M | $9M |
| — Investing Activities — | |||||
| Capital Expenditures | -$146K | -$46K | -$431K | -$234K | -$5M |
| Acquisitions (Net) | $0 | $0 | $0 | -$16M | -$10M |
| Investment Purchases | $0 | $0 | $0 | $0 | $5M |
| Investment Sales | $100K | $83K | $0 | $0 | $3M |
| Other Investing | $1M | $7K | -$1K | $0 | -$5M |
| Investing Cash Flow | $1M | $44K | -$431K | -$16M | -$12M |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $30K | $0 | $0 | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $0 | $0 | $0 | $475K | $60K |
| Financing Cash Flow | $725K | $566K | $2M | $28M | $60K |
| Net Change in Cash | $23K | -$119K | $487K | $4M | -$2M |
| Cash End of Period | $158K | $38K | $526K | $4M | $2M |
| Free Cash Flow | -$2M | -$779K | -$2M | -$9M | $4M |